Piper Sandler Maintains Neutral on Myriad Genetics, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst John Peterson has maintained a Neutral rating on Myriad Genetics (NASDAQ:MYGN) and raised the price target from $23 to $28.

May 13, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained a Neutral rating on Myriad Genetics but increased the price target from $23 to $28, indicating a positive outlook on the stock's value.
The increase in price target by Piper Sandler suggests a positive reassessment of Myriad Genetics' value, potentially leading to increased investor interest and a short-term positive impact on the stock price. The Neutral rating indicates that the analyst sees the company as adequately valued at current levels, but the raised target suggests an expectation of some growth or improvement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100